Edition:
United States

Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

1.22AUD
2 Dec 2016
Change (% chg)

$0.03 (+2.52%)
Prev Close
$1.19
Open
$1.20
Day's High
$1.25
Day's Low
$1.20
Volume
469,255
Avg. Vol
816,588
52-wk High
$3.03
52-wk Low
$1.01

MSB.AX

Chart for MSB.AX

About

Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced... (more)

Overall

Beta: 1.21
Market Cap(Mil.): $463.71
Shares Outstanding(Mil.): 381.65
Dividend: --
Yield (%): --

Financials

  MSB.AX Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -0.04 -- --
ROI: -1.60 -1.09 14.95
ROE: -2.24 -2.39 16.29

BRIEF-Mesoblast qtrly loss per share 5.24 cents

* Mesoblast provides corporate update and financial results for the first quarter ended September 30, 2016 Source text for Eikon: Further company coverage:

Nov 14 2016

BRIEF-Mesoblast names Bill Burns as vice chairman

* Mesoblast appoints Bill Burns, former chief executive of Roche Pharmaceuticals, as vice chairman Source text for Eikon: Further company coverage:

Sep 01 2016

BRIEF-Mesoblast reports Q4 earnings per share $0.1278

* Mesoblast reports financial results and operational highlights for the three months and for the year ended 30 june 2016

Aug 24 2016

BRIEF-Mesoblast intends to enter into strategic partnership advancing phase 3 development of allogeneic MPCS for biologic Refractory RA

* Phase 2 trial of mesoblast cell therapy shows dose-related clinical benefit in patients with biologic refractory rheumatoid arthritis

Aug 08 2016

Mesoblast cell treatment shows promise in rheumatoid arthritis : study

Mesoblast Ltd on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines, according to data from a mid-stage trial.

Aug 08 2016

Mesoblast cell treatment shows promise in rheumatoid arthritis -study

Aug 8 Mesoblast Ltd on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines, according to data from a mid-stage trial.

Aug 08 2016

BRIEF-Mesoblast provides update on heart failure trial and funding of clinical operations

* Mesoblast provides update on heart failure trial and funding of clinical operations Source text for Eikon: Further company coverage: )

Jul 01 2016

UPDATE 1-Mesoblast shares slump to 2009 low as Teva ends partnership

* Mesoblast shares plummet 42 pct to lows not seen since 2009

Jun 14 2016

Australia, NZ shares slump on Fed, Brexit worries

MELBOURNE/WELLINGTON, June 14 Australian shares dropped 2 percent on Tuesday to a one-month low while New Zealand fell for a second day tracking declines offshore on worries about U.S. growth and Britain potentially pulling out of the European Union.

Jun 14 2016

Mesoblast regains full rights to stem cell heart failure treatment

Mesoblast Ltd on Monday said it had regained full rights to its experimental stem cell therapy for advanced chronic heart failure, which is currently in late stage testing, from Teva Pharmaceutical Industries.

Jun 13 2016

Earnings vs. Estimates